The preparation of clinical grade 5-[123I]iodo-2'-deoxyuridine and 5-[125I]iodo-2'-deoxyuridine with high in vitro stability and the potential for early proliferation scintigraphy.

Details

Serval ID
serval:BIB_33420ED7604C
Type
Article: article from journal or magazin.
Publication sub-type
Case report (case report): feedback on an observation with a short commentary.
Collection
Publications
Institution
Title
The preparation of clinical grade 5-[123I]iodo-2'-deoxyuridine and 5-[125I]iodo-2'-deoxyuridine with high in vitro stability and the potential for early proliferation scintigraphy.
Journal
Nuclear Medicine Communications
Author(s)
Schaffland A.O., Delaloye A.B., Kosinski M., Dupertuis Y.M., Buchegger F.
ISSN
0143-3636
Publication state
Published
Issued date
05/2004
Peer-reviewed
Oui
Volume
25
Number
5
Pages
461-468
Language
english
Notes
Publication types: Comparative Study ; Evaluation Studies ; Journal Article ; Validation Studies. - Old month value: May
Abstract
BACKGROUND AND METHODS: 5-Iodo-2'-deoxyuridine (IdUrd) radiolabelled with the positron emitter I or with the gamma and Auger electron emitters I or I has been proposed for cancer diagnosis and therapy. We modified the synthesis to reliably obtain [I]IdUrd and [I]IdUrd by using an Iodogen supported destannylation reaction of 5-(tri-n-butylstannyl)-2'-deoxyuridine (Bu3SndUrd) which meets the requirements for good laboratory practice (GLP) and good clinical practice (GCP). A method of purification was developed to eliminate by-products as well as any unreacted starting material. RESULTS: [I]IdUrd, which originated from a trace of iodide in the Bu3SndUrd precursor, was identified as the unknown by-product reported for this method. This trace could be eliminated by modified purification of Bu3SndUrd. Stabilization of pH was essential for unequivocal identification of radiolabelled IdUrd and possible degradation products in the different systems tested for quality control. Biodistribution in tumour bearing nude mice was measured as early as 3 and 6 h after i.v. injection of [I]IdUrd. This compound showed high and specific activity uptake in tumour and dividing tissues when combined with 5-fluoro-2'-deoxyuridine pre-treatment. Uptake was specifically inhibited by injection of excess thymidine.
Keywords
Animals, Cell Division, Colonic Neoplasms/metabolism, Colonic Neoplasms/radionuclide imaging, Feasibility Studies, Female, Humans, Idoxuridine/chemical synthesis, Idoxuridine/diagnostic use, Iodine Radioisotopes/chemistry, Iodine Radioisotopes/diagnostic use, Isotope Labeling/methods, Metabolic Clearance Rate, Mice, Mice, Nude, Neoplasm Staging/methods, Organ Specificity, Radiopharmaceuticals/chemical synthesis, Radiopharmaceuticals/diagnostic use, Reproducibility of Results, Sensitivity and Specificity, Tissue Distribution
Pubmed
Web of science
Create date
25/01/2008 11:27
Last modification date
20/08/2019 13:19
Usage data